Dr. Hoyt Gazaway, MD

 Hoyt Wayborn Gazaway, M.D, F.A.C.S.

Bostock Family Medicine Gwinnett Medical Group

771 Old Norcross Rd, Suite 255

Lawrenceville, GA 30046

Tel: (404)901-4075 Fax: (770)339-4585

Email: [email protected]

Clinical Training & Certification:

CITI program for the protection of research participants training (Health Information Privacy and Security) (Biomedical Research)

Good Clinical Practices (GCP) trained

Work Experience: 

Clinical Research Primary and Sub-Investigator at One Health Research Clinic, Inc. Feb, 2017 -Present

Clinical Research Sub-Investigator at Perimeter Institute for Clinical Research, Inc 2014 - 2017

William Bostock & Associates Family Medicine (Pediatrics and Adults) Oct, 2011 - Present

 Buford  Complete  Health  and Wellness Center Mar, 2006 - Oct 2011

Clinical  Director of Truth's Community  Clinic,  providing  medical, dental and pharmacy needs to the poor 2003 - Present

Southern Surgical Associates 1992 - Mar, 2006

Carraway Methodist Medical Center, Birmingham, Alabama (Internship/Residency - General Surgery) 1987 -1992

Education:

Medical College of Georgia, Augusta, Georgia M.D Academic Achievement: Summa cum Laude 1987

Professional Certification:

American Board of Surgery, Board Certified 1993

Fellow of the American College of Surgeons 1995 

Professional Society Memberships:

American Medical Association 1992

Gwinnett/Forsyth County Medical Society 1992

American Board of Surgery, Diplomate 1993

Fellow of the American College of Surgeons 1995

Professional Honors:

Alpha Omega Alpha Honor Medical Society 1986

Clinical Research Trial Expirience: 

BAY98-7106/14725: A multicenter, randomized, double-blind, active-controlled study of nifedipine GITS and candesartan in fixed-dose combination in adult subjects with moderate to severe essential hypertension who are naYve to any anti-hypertensive drug treatment (Bayer); 2013.

A Randomized, Double Blind, Placebo-Controlled, Phase m Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea­ Predominant Irritable Bowel syndrome; Study# 270189661B83002; Furiex Pharmaceuticals; 2013

A Phase ill Clinical Trial to Study the Safety and Efficacy ofMK-1293 Compared to Lantus in Subjects With Type 1 Diabetes Mellitus, Merck Sharp & Dahme Corporation, Principal Investigator, 2013-2016 

A Randomized, Placebo-controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment with Exenatide Once Weekly in Patients with Type 2 Diabetes Mellitus, Duke University/ Amylin Pharmaceuticals, LLC, Principal Investigator, 6/2013- 2016.

A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects with Gout and Cardiovascular Comorbidities. Takeda, 2014.

Effect of Liraglutide on Body Weight in Non-Diabetic Obese Subjects or Overweight Subjects with Co-Morbidities. A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multi­ Centre, Multinational Trial with Stratification of Subject to either 56 or 160 Weeks of Treatment Based on pre-Diabetes Status at Randomization. Novo Nordisk, 7/2014.

A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When AMG 145 is Used in Combination With Statin Therapy in Patients with Clinically Evident  Cardiovascular Disease. Amgen, Inc., 7/2014.

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea­ Predominant Irritable Bowel Syndrome. Furiex Pharmaceuticals, Sub-Investigator, 11/2012- 8/2014.

A Multicenter Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat versus Placebo on Renal Function in Hyperuricemia and Moderate to Severe Renal Impairment. Takeda, 2014.

AMG 20120138: A Multicenter, Controlled, Open-label Extension (OLE) Study to assess the Long-term Safety and Efficacy of AMO 145 (Amgen); 2013-2016.

AMO 20110116: A Double-blind, Randomized, Multicenter Study to Evaluate Safety and Efficacy of AMO 145, Compared With Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of a HMG-CoA Reductase Inhibitor (Amgen); 2013- 2016.

A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When AMO 145 is Used in Combination With Statin Therapy in Patients with Clinically Evident Cardiovascular Disease. Amgen, Inc, 2014- 2016.

Phase III Trial to Confirm the Anti-angina! Effect of T89 in Patients with Stable Angina (CAESA Study), Tasly Pharmaceuticals, Inc, Principal Investigator, 7/2014-2016.

A Phase 2, Randomized , Double-Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects with Gout and Moderate Renal Impairment, Takeda Development Center Americas, Inc, Principal Investigator, 8/2014-2016.

A Phase III, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Ertugliflozin (MK-8835/PF-04971729) with Sitagliptin Compared with Ertugliflozin Alone and Sitagliptin Alone, in the Treatment of Subjects with T2DM With Inadequate Glycemic Control on Metformin Monotherapy, Merck Sharp & Dohme Corporation, Principal Investigator, 12/2014- 2016.

A Randomized, double-blind, double-dummy, parallel-group, multi-center Phase IIb study to assess the efficacy and safety of different dose combinations of an aromatase inhibitor and a progestin in an intravaginal ring versus placebo and leuprorelin/ leuprolide acetate in women with symptomatic endometriosis over a 12 week  treatment period;   Bayer HealthCare AG; Study Number:    Bay 98-7196 I 15832; 2015

"A Phase 2 Randomized, Double-Blind, Placebo-Controlled Parallel Group Multi-Center Study To Evaluate The Efficacy and Safety ofTTP273 Following of 12 Weeks Administration In Subject With Type 2 Diabetes Mellitus On a Stable Dose of Metformin"; Sponsor: vTv Therapeutics; Protocol#; TTP273-201; 5/ 2016-2017

A Phase III Study to Evaluate the Efficacy and Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women; Protocol#: M12-815; Sponsor: AbbVie; 4/2016-2017

A Phase III Study to Evaluate the Efficacy and Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis Associated Pain; Protocol#: M12-702; Sponsor: AbbVie; 4/2016- 2017

A Phase 3 Double-Blind, Placebo-Controlled study to assess the efficacy, safety, and tolerability ofNKTR-181 in Opioid Naive Subjects with Moderate to Severe Chronic Low Back Pain; Nektar Therapeutics; Protocol Number: 14-181-07; 3/2016

A Phase 3 Double-Blind, Placebo-Controlled study to assess the efficacy, safety, and tolerability ofNKTR-181 in Opioid Naive Subjects with Moderate to Severe Chronic Noncancer Pain; Nektar Therapeutics; Protocol Number: 14-181-08; 3/ 2016

A Phase 3 Randomized, Double-Blind, Active-Controlled, Multicenter Study of The Long-Term Safety and Efficacy Of Subcutaneous administration Of Tanezumab In Subjects With Osteoarthritis Of The Hip Or Knee; Sponsor: Pfizer; Protocol#: A4091058; 3/2016

A Phase 3, Multicenter, Long-Term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement; Sponsor: Pfizer; Protocol #: A4091064; 3/ 2016.

A Phase 2 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVNIOOO in Subjects with External Genital Warts and Perianal Warts; Sponsor: Novan, Inc.; Protocol#: NI-WA201; 5/2016.

A Phase 3 Double-Blind, Placebo-Controlled study to  assess  the efficacy,  safety,  and tolerability ofNKTR-181 in Opioid Naive Subjects with Moderate to Severe Chronic Low Back Pain; Nektar Therapeutics; Protocol Number: 14-181-07; 2016.

A randomized, double blind, placebo-controlled, phase 2b dose ranging study to assess the efficacy and safety of OBE2l 09 in subject with endometriosis associated pain.

A Phase 3, multicenter, randomized, double-blind, placebo-controlled study investigating the efficacy and safety of daily oral administration of OBE2109 alone and in combination with add­ back therapy for management of heavy menstrual bleeding associated with uterine fibroids in premenopausal woman.

Liberty 2: An International Phase 3 Randomized, Double-blind, Placebo-Controlled Efficiancy and Safety study to Evaluate Relugolix Co-Administered with and ,without Low-Dose Estradiol and Norethindrone Acetate in Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids.

Spitit l: An International Phase 3 Randomized, Double -blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolis Administered with and sithout Low-Dose Estrodiol and Norc1hindrone Acetate in Women with Endometriosis-Associated Pain.

A 26 week, Multicenter, Randomized, Placebo-Controlled, Double Blind, Parallel Group, Phase 3 Trial with a 26 week Safety Extention Period Evaluating the Safety and Efficacy of Dapagliflozin 5 and 10 mg, and Saxagliptin 2.5 and 5 mg in Pediatric Patients with Type 2 Diabetes Mellitus who are between 10 and below 18 years of age

A Phase 3, Open-lable, Multicenter, 12 month Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed with Attention-deficit/Hyperactiveity Disorder.

A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Fixed-Dose, Efficacy, and Sfery Study ofSHP465 in Children Aged 6-12 years with Attention-Deficit/Hyperactive Disorder(ADHD) 

A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Testicular

Safety of Filgotinib in Adult Males with Moderately to Severely Active Ulcerative Colitis

A Randomized, Double blind, Placebo-controlled Phase 2 Study to Evaluate the Testicular Safety of  Filgotinib in Adult Males with Moderately to Severely to Severely Active Inflamatory Bowl Disease.